Elizabeth Jungman directs Pew’s work on drug safety and innovation, overseeing Pew’s initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse. Before joining Pew, she served as a senior health policy adviser with the Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures. Before moving to the Hill, Jungman was in private legal practice, where she counseled clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She has an undergraduate biology degree from Harvard College, a J.D. from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
A new federal law, the Drug Supply Chain Security Act, passed in 2013, will help protect patients by better securing our nation’s pharmaceutical supply chain. Read More
Pew Testimony on Antibiotic Resistance Before the Presidents Council of Advisors on Science and Technology
The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antibiotic resistance. Senior director of drugs and medical devices Allan Coukell testified on the need to spur the development of new antibacterial drugs and to better collect data on antibiotic use both in both agriculture and humans. Read More
Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a Centers for Disease Control and Prevention report, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die.1 Doctors routinely encounter patients with infections that do not respond to available treatment, and when new... Read More